WO2008105515A1 - 新規なヒドロキサム酸誘導体 - Google Patents

新規なヒドロキサム酸誘導体 Download PDF

Info

Publication number
WO2008105515A1
WO2008105515A1 PCT/JP2008/053573 JP2008053573W WO2008105515A1 WO 2008105515 A1 WO2008105515 A1 WO 2008105515A1 JP 2008053573 W JP2008053573 W JP 2008053573W WO 2008105515 A1 WO2008105515 A1 WO 2008105515A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivative
hydroxamic acid
novel hydroxamic
disclosed
novel
Prior art date
Application number
PCT/JP2008/053573
Other languages
English (en)
French (fr)
Inventor
Hajime Takashima
Mitsukane Yoshinaga
Yasunobu Ushiki
Risa Tsuruta
Hiroki Urabe
Tetsuya Tanikawa
Katsuhiko Tanabe
Yasutaka Baba
Mai Yokotani
Yasuko Kawaguchi
Hironori Kotsubo
Yasuhiro Tsutsui
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to JP2009501309A priority Critical patent/JP5227304B2/ja
Publication of WO2008105515A1 publication Critical patent/WO2008105515A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

　本発明の課題は、LpxC 阻害作用に基づいて、緑膿菌等のグラム陰性細菌及びその薬剤耐性菌に対して強い抗菌活性を示し、医薬品として有用な新規な化合物を提供することである。一般式（１）で表されるヒドロキサム酸誘導体又はその薬学的に許容される塩を提供する。
PCT/JP2008/053573 2007-02-28 2008-02-28 新規なヒドロキサム酸誘導体 WO2008105515A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009501309A JP5227304B2 (ja) 2007-02-28 2008-02-28 新規なヒドロキサム酸誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-050739 2007-02-28
JP2007050739 2007-02-28

Publications (1)

Publication Number Publication Date
WO2008105515A1 true WO2008105515A1 (ja) 2008-09-04

Family

ID=39721337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053573 WO2008105515A1 (ja) 2007-02-28 2008-02-28 新規なヒドロキサム酸誘導体

Country Status (2)

Country Link
JP (1) JP5227304B2 (ja)
WO (1) WO2008105515A1 (ja)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084543A1 (ja) * 2007-12-27 2009-07-09 Idemitsu Kosan Co., Ltd. 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
WO2010024356A1 (ja) * 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
US8624034B2 (en) 2011-03-07 2014-01-07 Pfizer Inc. Fluoro-pyridinone derivatives useful as antibacterial agents
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
US20140139786A1 (en) * 2012-11-21 2014-05-22 Merck Patent Gmbh Polymerisable compounds and the use thereof in liquid-crystal displays
US8748466B2 (en) 2011-04-08 2014-06-10 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
US8809333B2 (en) 2011-04-08 2014-08-19 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2014165075A1 (en) 2013-03-12 2014-10-09 Achaogen, Inc. Antibacterial agents
US20150057260A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Alkynyl alcohols and methods of use
WO2016039433A1 (ja) * 2014-09-12 2016-03-17 富山化学工業株式会社 新規なヒドロキサム酸誘導体またはその塩を含有する医薬組成物
JP2016508487A (ja) * 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
US9617256B2 (en) 2007-06-12 2017-04-11 Achaogen, Inc. Antibacterial agents
WO2017223349A1 (en) 2016-06-23 2017-12-28 Achaogen, Inc. Antibacterial agents
US9908851B2 (en) 2013-08-16 2018-03-06 Duke University 2-piperidinyl substituted N,3-dihydroxybutanamides
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
CN109574980A (zh) * 2018-11-28 2019-04-05 云南大学 基于罗丹明衍生物检测一氧化氮的荧光探针分子、制备及用途
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
US10550117B2 (en) 2016-08-24 2020-02-04 Genentech, Inc. 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
US10597361B2 (en) 2010-09-03 2020-03-24 Duke University Ethynylbenzene derivatives
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
CN111867600A (zh) * 2018-03-15 2020-10-30 辉瑞大药厂 用作抗菌剂的吡啶酮和嘧啶酮磷酸盐和硼酸盐
CN115448919A (zh) * 2022-10-31 2022-12-09 滨州医学院附属医院 一种海洋来源的萘啶类抗炎活性化合物及其制备方法
EP4140994A1 (en) * 2021-08-26 2023-03-01 Idemitsu Kosan Co., Ltd. Compound, material for an organic electroluminescence device and an organic electroluminescence device comprising the compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870712A (en) * 1972-03-17 1975-03-11 Lilly Co Eli Cinchoninic acid derivatives
JP2006519772A (ja) * 2003-01-08 2006-08-31 カイロン コーポレイション 抗菌剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870712A (en) * 1972-03-17 1975-03-11 Lilly Co Eli Cinchoninic acid derivatives
JP2006519772A (ja) * 2003-01-08 2006-08-31 カイロン コーポレイション 抗菌剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KADAM R.U. ET AL.: "Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 19, 2006, pages 5136 - 5143, XP005611710 *
KLINE T. ET AL.: "Potent, Novel in Vitro Inhibitors of the Pseudomonas aeruginosa Deacetylase LpxC", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 14, 2002, pages 3112 - 3129, XP008045411 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617256B2 (en) 2007-06-12 2017-04-11 Achaogen, Inc. Antibacterial agents
WO2009084543A1 (ja) * 2007-12-27 2009-07-09 Idemitsu Kosan Co., Ltd. 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
US8945724B2 (en) 2007-12-27 2015-02-03 Idemitsu Kosan Co., Ltd. Nitrogen-containing heterocyclic derivative and organic electroluminescent device using the same
WO2010024356A1 (ja) * 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
US9340493B2 (en) 2008-09-19 2016-05-17 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
US8664401B2 (en) 2009-12-16 2014-03-04 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
US9180123B2 (en) 2009-12-16 2015-11-10 Pfizer Inc. N-link hydroxamic acid derivatives useful as antibacterial agents
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
US9018384B2 (en) 2009-12-16 2015-04-28 Pfizer Inc. N-link hydroxamic acid derivatives useful as antibacterial agents
US8846933B2 (en) 2009-12-16 2014-09-30 Pfizer Inc. N-link hydroxamic acid derivatives useful as antibacterial agents
US10597361B2 (en) 2010-09-03 2020-03-24 Duke University Ethynylbenzene derivatives
US8779148B2 (en) 2011-03-07 2014-07-15 Pfizer Inc. Fluoro-pyridinone derivatives useful as antibacterial agents
US8624034B2 (en) 2011-03-07 2014-01-07 Pfizer Inc. Fluoro-pyridinone derivatives useful as antibacterial agents
US8809333B2 (en) 2011-04-08 2014-08-19 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US8748466B2 (en) 2011-04-08 2014-06-10 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
US9403758B2 (en) 2012-05-10 2016-08-02 Achaogen, Inc. Antibacterial agents
US9701622B2 (en) 2012-05-10 2017-07-11 Achaogen, Inc. Antibacterial agents
WO2013170165A1 (en) * 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
CN107267159A (zh) * 2012-11-21 2017-10-20 默克专利股份有限公司 可聚合化合物和其在液晶显示器中的用途
US20140139786A1 (en) * 2012-11-21 2014-05-22 Merck Patent Gmbh Polymerisable compounds and the use thereof in liquid-crystal displays
JP2016508487A (ja) * 2013-01-28 2016-03-22 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
EP2948450A4 (en) * 2013-01-28 2016-11-09 Viamet Pharmaceuticals Inc METALLOENZYMINHIBITORVERBINDUNGEN
US9663488B2 (en) 2013-01-28 2017-05-30 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2014209107B2 (en) * 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2014165075A1 (en) 2013-03-12 2014-10-09 Achaogen, Inc. Antibacterial agents
US9908851B2 (en) 2013-08-16 2018-03-06 Duke University 2-piperidinyl substituted N,3-dihydroxybutanamides
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
US20160185797A1 (en) * 2013-08-22 2016-06-30 Genentech, Inc. Alkynyl alcohols and methods of use
US20150057260A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Alkynyl alcohols and methods of use
WO2016039433A1 (ja) * 2014-09-12 2016-03-17 富山化学工業株式会社 新規なヒドロキサム酸誘導体またはその塩を含有する医薬組成物
US10149911B2 (en) 2014-09-12 2018-12-11 Toyama Chemical Co., Ltd. Pharmaceutical composition containing hydroxamic acid derivative or salt thereof
WO2017223349A1 (en) 2016-06-23 2017-12-28 Achaogen, Inc. Antibacterial agents
US10550117B2 (en) 2016-08-24 2020-02-04 Genentech, Inc. 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
CN111867600A (zh) * 2018-03-15 2020-10-30 辉瑞大药厂 用作抗菌剂的吡啶酮和嘧啶酮磷酸盐和硼酸盐
CN109574980A (zh) * 2018-11-28 2019-04-05 云南大学 基于罗丹明衍生物检测一氧化氮的荧光探针分子、制备及用途
EP4140994A1 (en) * 2021-08-26 2023-03-01 Idemitsu Kosan Co., Ltd. Compound, material for an organic electroluminescence device and an organic electroluminescence device comprising the compound
WO2023027196A1 (en) * 2021-08-26 2023-03-02 Idemitsu Kosan Co., Ltd. Compound, material for an organic electroluminescence device and an organic electroluminescence device comprising the compound
CN115448919A (zh) * 2022-10-31 2022-12-09 滨州医学院附属医院 一种海洋来源的萘啶类抗炎活性化合物及其制备方法
CN115448919B (zh) * 2022-10-31 2024-01-26 滨州医学院附属医院 一种海洋来源的萘啶类抗炎活性化合物及其制备方法

Also Published As

Publication number Publication date
JPWO2008105515A1 (ja) 2010-06-03
JP5227304B2 (ja) 2013-07-03

Similar Documents

Publication Publication Date Title
WO2008105515A1 (ja) 新規なヒドロキサム酸誘導体
CY1121761T1 (el) Παραγωγο υδροξαμικου οξεος
WO2008143343A1 (ja) １４位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
TW200728307A (en) Novel spirochromanone derivatives
WO2009020140A1 (ja) アダマンチルウレア誘導体
HRP20120323T1 (en) Diarylhydantoin compounds
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP1704856A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2006027711A3 (en) Prodrugs and codrugs containing bio- cleavable disulfide linkers
WO2007081597A3 (en) Peri condensed tricyclic compounds useful as antibacterial agents
HK1076816A1 (ja)
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
WO2010066629A3 (en) Novel azaindoles
WO2007053844A3 (en) Compositions and methods for treating inflammatory disorders
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2005089733A3 (en) Anti-adhesive compounds to prevent and treat bacterial infections
WO2003053915A3 (en) Compounds for the treatment of inflammatory disorders
WO2006127379A3 (en) Par2-modulating compounds and their use
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2008153129A1 (ja) 尿酸値低下剤
PH12021551143A1 (en) Novel imidazole derivative
WO2009051223A1 (ja) 白内障処置のための医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721022

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009501309

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721022

Country of ref document: EP

Kind code of ref document: A1